BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15646801)

  • 1. Rolipram, a phosphodiesterase 4 inhibitor, stimulates osteoclast formation by inducing TRANCE expression in mouse calvarial cells.
    Cho ES; Yu JH; Kim MS; Yim M
    Arch Pharm Res; 2004 Dec; 27(12):1258-62. PubMed ID: 15646801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rolipram, a phosphodiesterase 4 inhibitor, suppresses PGE2-induced osteoclast formation by lowering osteoclast progenitor cell viability.
    Park H; Yim M
    Arch Pharm Res; 2007 Apr; 30(4):486-92. PubMed ID: 17489366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways.
    Takami M; Cho ES; Lee SY; Kamijo R; Yim M
    FEBS Lett; 2005 Jan; 579(3):832-8. PubMed ID: 15670856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts.
    Park H; Young Lee S; Lee DS; Yim M
    Biochem Biophys Res Commun; 2007 Mar; 354(1):178-83. PubMed ID: 17222389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis.
    Tsurukai T; Udagawa N; Matsuzaki K; Takahashi N; Suda T
    J Bone Miner Metab; 2000; 18(4):177-84. PubMed ID: 10874596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rolipram, a phosphodiesterase 4 inhibitor, stimulates inducible cAMP early repressor expression in osteoblasts.
    Cho ES; Yu JH; Kim MS; Yim M
    Yonsei Med J; 2005 Feb; 46(1):149-54. PubMed ID: 15744818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N; Udagawa N; Suda T
    Biochem Biophys Res Commun; 1999 Mar; 256(3):449-55. PubMed ID: 10080918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
    Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
    J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2.
    Yamagami H; Nishioka T; Ochiai E; Fukushima K; Nomura M; Kasugai S; Moritani S; Yokogawa K; Miyamoto K
    Biochem Pharmacol; 2003 Sep; 66(5):801-7. PubMed ID: 12948861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 4 inhibitor rolipram potentiates the inhibitory effect of calcitonin on osteoclastogenesis.
    Miyamoto K; Nishioka T; Waki Y; Nomura M; Katsuta H; Yokogawa K; Amano H
    J Bone Miner Metab; 2006; 24(4):260-5. PubMed ID: 16816919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts.
    Yang S; Takahashi N; Yamashita T; Sato N; Takahashi M; Mogi M; Uematsu T; Kobayashi Y; Nakamichi Y; Takeda K; Akira S; Takada H; Udagawa N; Furusawa K
    J Immunol; 2005 Aug; 175(3):1956-64. PubMed ID: 16034140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process.
    Terry R; Cheung YF; Praestegaard M; Baillie GS; Huston E; Gall I; Adams DR; Houslay MD
    Cell Signal; 2003 Oct; 15(10):955-71. PubMed ID: 12873709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
    Palmqvist P; Persson E; Conaway HH; Lerner UH
    J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.
    Komine M; Kukita A; Kukita T; Ogata Y; Hotokebuchi T; Kohashi O
    Bone; 2001 May; 28(5):474-83. PubMed ID: 11344046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.